|Zalicus gains on publication of data. Savient launches gout drug|
|By BioMedReports.com Staff|
|Friday, 25 February 2011 19:42|
Shares of Zalicus Inc. (NASDAQ:ZLCS) moved higher today after the company announced the publication of preclinical data in the journal PAIN. The paper describes the activity of Z212, a novel proprietary small organic compound that acts to modulate Nav1.7 and Nav1.8 sodium channels and to reduce neuropathic pain by targeting the hyper-excitability associated with chronic pain signaling pathways. Through its unique mechanism of action, Z212 has been shown to both reduce the excitability of neurons and reverse pain hypersensitivity in preclinical models. Zalicus is utilizing its ion channel discovery platform and scientific expertise to develop a pipeline of novel, orally active compounds targeting critical N-type and T-type calcium and selected sodium channels implicated in chronic pain.
Zalicus’s most advanced preclinical ion channel product candidate, Z944, a novel T-type calcium channel blocker, has been selected to advance into IND-enabling toxicology studies prior to the initiation of a Phase 1 study in 2011. Z212 and multiple other preclinical compounds have been identified and are being evaluated for additional clinical starts in 2011.
In the paper entitled, "A novel slow-inactivation-specific ion channel modulator attenuates neuropathic pain," Hildebrand et al., PAIN (2011), Zalicus researchers describe the design, synthesis and activity of the unique sodium channel pain blocking compound Z212 to preferentially attenuate hyperexcitable neurons while largely sparing normally firing neurons.
"By targeting the sodium channels in the peripheral and central nociceptive signaling pathways through its unique mechanism of action, Z212 has the potential to become a safe and effective treatment for chronic inflammatory and neuropathic pain," commented Mark H.N. Corrigan, MD, President and CEO of Zalicus. "With the addition of selected sodium channel targets to its screening platform Zalicus continues to utilize its considerable expertise in ion channels to develop a pipeline of novel, orally available agents that address these attractive targets for pain intervention."
Shares of Zalicus gained 15 cents or 7.28% to $2.21.
"Since receiving FDA approval for KRYSTEXXA, we have focused on preparing for a successful U.S. launch," said John H. Johnson, Chief Executive Officer of Savient. "Our sales force has completed very thorough and extensive training. We are excited to deploy this highly talented and biologics experienced team into their territories. There has never been a more exciting time in the history of Savient, nor for the chronic gout patients, who have waited so long for a therapy that has the potential to change the course of their lives."
Shares of Savient added 39 cents or 4% to $9.85.
Cadence Pharmaceuticals, Inc. (Nasdaq:CADX) , a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today announced that it will release its fourth quarter and full year ended December 31, 2010 financial results on Friday, March 4, 2011.
GeoVax Labs, Inc. (OTC Bulletin Board:GOVX), an Atlanta-based biotechnology company that creates, develops, and tests innovative HIV/AIDS vaccines, today announced its financial results for the fourth quarter and year ended December 31, 2010.